ClinicalTrials.gg
CompletedNCT07320521Updated Jun 8, 2026

A Study to Assess the Mass Balance of [14C]HRS-8080 in Healthy Chinese Postmenopausal Female Subjects.

A Phase 1 interventional study of [14C]HRS-8080 in Breast Cancer, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to female participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing HRS-8080 in Breast Neoplasms — 8 open to participants now, 8 under way, 3 of them phase 3. HRS-8080 · Breast Neoplasms.

Enrollment
11th of 11
6 · median 180
Started
2026
with 4 others
Phase 1
4 of 11
1 open now
Registered
7th of 11
by date
Lead sponsor
11 of 11
Shandong Suncadia Medicine Co., Ltd.

Among the 11 studies testing HRS-8080 in Breast Neoplasms, this one is the 11th largest by enrollment, is one of 5 that started in 2026, is one of 4 in phase 1, and was the 7th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 11 studies testing HRS-8080 in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About HRS-8080

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 70 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing HRS-8080 in Breast Neoplasms, or all of them as a file.
02

Study summary

This single-part, healthy volunteer study will try to identify how the test medicine is taken up, broken down and removed from the body. To help investigate this, the test medicine is radiolabelled, which means that the test medicine has a radioactive component (carbon-14) which helps us to track where the test medicine is in the body. The safety and tolerability of the test medicine will also be studied.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy female.
  2. Body weight must be ≥45 kg at screening, and (BMI) must be within the range of 19 kg/m² to 26 kg/m² (inclusive).
  3. The subject must have regular bowel movements.

Exclusion criteria

Exclusion Criteria:

  1. Any disease or disorder that the researcher believes may pose a risk to the researcher due to participation in the study, or may affect the research results.
  2. Have participated in blood donation within 3 months prior to screening, with a blood donation volume of ≥400 mL or a blood loss of ≥400 mL; Have participated in blood donation within one month and donated at least 200 mL of blood or lost at least 200 mL of blood; Those who receive blood transfusion within one month or plan to donate blood within three months after the end of this trial.
  3. Having taken any clinical trial drug or participated in any drug clinical trial within the three months prior to the screening period.
  4. Those who have received a vaccine within one month before screening or plan to receive a vaccine during the trial period.
  5. People with allergic constitutions, such as those with a known history of allergy to two or more substances; Or those who, as determined by the researchers, may be allergic to the drug or its .
  6. Those with a history of fainting at the sight of needles or blood may have difficulty in blood collection or cannot tolerate venipuncture for blood collection.
  7. Workers engaged in work that requires long-term exposure to radioactive conditions; Or those who have had significant radioactive exposure within one year prior to the test or have participated in radioactive drug labeling tests.
  8. Those who show abnormal results through comprehensive physical examination, vital signs, laboratory tests, 12-lead , chest X-ray, digital rectal examination, and abdominal B-ultrasound, and are determined by the researcher to have clinical significance.
  9. Sex hormones: Those with abnormal tests for luteinizing hormone (LH), progesterone (P), testosterone (T), and prolactin (PRL), and who are determined by the researcher to have clinical significance.
  10. Excessive drinking or frequent alcohol consumption within the six months prior to the screening period, that is, consuming more than 14 units of alcohol per week (1 unit =360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine); Or the result of the alcohol breath test during the screening period is ≥20 mg/dl; Or those who are unable to quit alcohol during the trial period.
  11. Those who smoked more than five cigarettes per day or habitually used nicotine-containing products in the three months prior to the screening period; Or those who are unable to withdraw during the trial period.
  12. Abuse of drugs or use of soft drugs (such as marijuana) in the three months prior to the screening period or use of hard drugs (such as cocaine, amphetamines, etc.) in the year prior to the screening period; Or positive urine drug abuse (drug) test during the screening period.
  13. Those who habitually consume grapefruit juice or excessive amounts of tea, coffee and/or caffeinated beverages and are unable to quit during the trial period.
  14. Any significant abnormalities in the 12-lead electrocardiogram during screening were considered clinically significant by the researchers.
  15. Those with any history of serious clinical diseases or diseases or conditions that the researcher believes may affect the trial results, such as a history of gastrointestinal, liver or kidney diseases or current existence of such diseases, or any diseases known to interfere with drug absorption, distribution, metabolism or excretion.
  16. Those who test positive for any one of surface antigen or hepatitis B e antigen, virus antibody, Treponema pallidum antibody, or the combined test of antigen/antibody.
  17. There was evidence of renal insufficiency during screening.
  18. Those who have undergone major surgery within 6 months prior to the screening period or whose surgical incisions have not fully healed; Major surgeries include but are not limited to those with significant bleeding risks, prolonged general anesthesia periods, or incision or obvious traumatic injuries.
  19. Hemorrhoids or perianal diseases accompanied by regular or ongoing bleeding during defecation; Subjects who are unable to swallow, or have a history of gastrointestinal dysfunction such as irritable bowel syndrome, inflammatory bowel disease, or have undergone surgeries like gastrectomy, which the researchers determine may affect drug absorption, as well as those with habitual constipation or diarrhea.
  20. Any drugs that inhibit or induce the activity of liver drug-metabolizing enzymes or transporters have been used within 30 days prior to screening.
  21. In the 14 days prior to screening or currently using any prescription drugs, over-the-counter drugs, vitamin products, health supplements or Chinese herbal medicines, etc., unless it has been evaluated that the use of such drugs will not interfere with the research objectives and will not endanger the safety of the subjects.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C]HRS-8080 Group

    Drug: [14C]HRS-8080

Interventions

  • Subjects will receive single dose of orally \[14C\]HRS-8080.

06

What researchers measure

Primary outcomes

  1. The cumulative amount of HRS-8080 excreted.

    Time frame: 0 hour to 360 hours.

  2. Percentage of parent drug and its metabolite(s) relative to total radioactive exposure in plasma.

    Time frame: 0 hour to 360 hours.

  3. Percentage of administered dose excreted as parent drug and its metabolite(s) in urine.

    Time frame: 0 hour to 360 hours.

  4. Percentage of administered dose excreted as parent drug and its metabolite(s) in feces.

    Time frame: 0 hour to 360 hours.

  5. Maximum concentration (Cmax).

    Pharmacokinetic parameters for total radioactivity in plasma.

    Time frame: 0 hour to 336 hours.

  6. Time of maximum concentration (Tmax).

    Pharmacokinetic parameters for total radioactivity in plasma.

    Time frame: 0 hour to 336 hours.

  7. Area under the concentration-time curve (AUC).

    Pharmacokinetic parameters for total radioactivity in plasma.

    Time frame: 0 hour to 336 hours.

  8. Elimination half-life (t1/2).

    Pharmacokinetic parameters for total radioactivity in plasma.

    Time frame: 0 hour to 336 hours.

  9. Apparent clearance (CL/F).

    Pharmacokinetic parameters for total radioactivity in plasma.

    Time frame: 0 hour to 336 hours.

  10. Apparent volume of distribution (Vz/F).

    Pharmacokinetic parameters for total radioactivity in plasma.

    Time frame: 0 hour to 336 hours.

  11. Ratio of total radioactivity in whole blood to plasma.

    Time frame: 0 hour to 360 hours.

Secondary outcomes

  1. Maximum concentration (Cmax).

    Pharmacokinetic parameters for HRS-8080 and its metabolite(s) in plasma.

    Time frame: 0 hour to 336 hours.

  2. Time of maximum concentration (Tmax).

    Pharmacokinetic parameters for HRS-8080 and its metabolite(s) in plasma.

    Time frame: 0 hour to 336 hours.

  3. Area under the concentration-time curve (AUC).

    Pharmacokinetic parameters for HRS-8080 and its metabolite(s) in plasma.

    Time frame: 0 hour to 336 hours.

  4. Elimination half-life (t1/2).

    Pharmacokinetic parameters for HRS-8080 and its metabolite(s) in plasma.

    Time frame: 0 hour to 336 hours.

  5. Apparent clearance (CL/F).

    Pharmacokinetic parameters for HRS-8080 and its metabolite(s) in plasma.

    Time frame: 0 hour to 336 hours.

  6. Apparent volume of distribution (Vz/F).

    Pharmacokinetic parameters for HRS-8080 and its metabolite(s) in plasma.

    Time frame: 0 hour to 336 hours.

  7. Adverse events (AEs).

    Time frame: Day -7 to Day 23.

07

Study locations

1 site
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in Jan 2026, 0 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 0 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Jan 6, 2026
StartActual
Jan 9, 2026
Primary completionActual
Jan 28, 2026
CompletionActual
Jan 28, 2026
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07320521
Responsible party
Sponsor
First posted
Jan 6, 2026
Start date
Jan 9, 2026
Primary completion
Jan 28, 2026
Completion
Jan 28, 2026
Last update
Jun 8, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-8080

Start the discussion